Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd. Completes National Market Access for Its 9-Valent HPV Vaccine

Stock News05-29

Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd. announced that its wholly-owned subsidiary, Xiamen Wantai Canghai Biotech Co., Ltd., has successfully completed the national market access process for its 9-valent human papillomavirus vaccine across mainland China. The vaccine has now gained access in all 31 provincial-level regions and is available through approximately 2,300 disease control and prevention centers, covering around 13,000 vaccination points nationwide. This milestone signifies that the domestically produced 9-valent HPV vaccine has secured the qualification for nationwide supply. Following this achievement, Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd.'s product portfolio now includes both its 9-valent and 2-valent HPV vaccines, creating a differentiated product matrix covering the female population aged 9 to 45. This effectively meets diverse vaccination needs across different age groups and consumer capabilities, further enriching the company's product line. The expansion enhances the company's comprehensive competitiveness in the HPV vaccine sector and lays a solid foundation for its long-term stable development. As the distribution of the 9-valent HPV vaccine continues to scale up, it is expected to gradually generate new revenue and profit growth, thereby improving the company's profitability.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1123248946?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-29 16:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1123248946","market":"sg","top_or_hot":-1,"title":"Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd. Completes National Market Access for Its 9-Valent HPV Vaccine","media":"Stock News","content":"<p>Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd. announced that its wholly-owned subsidiary, Xiamen Wantai Canghai Biotech Co., Ltd., has successfully completed the national market access process for its 9-valent human papillomavirus vaccine across mainland China. The vaccine has now gained access in all 31 provincial-level regions and is available through approximately 2,300 disease control and prevention centers, covering around 13,000 vaccination points nationwide. This milestone signifies that the domestically produced 9-valent HPV vaccine has secured the qualification for nationwide supply. Following this achievement, Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd.'s product portfolio now includes both its 9-valent and 2-valent HPV vaccines, creating a differentiated product matrix covering the female population aged 9 to 45. This effectively meets diverse vaccination needs across different age groups and consumer capabilities, further enriching the company's product line. The expansion enhances the company's comprehensive competitiveness in the HPV vaccine sector and lays a solid foundation for its long-term stable development. As the distribution of the 9-valent HPV vaccine continues to scale up, it is expected to gradually generate new revenue and profit growth, thereby improving the company's profitability.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd. Completes National Market Access for Its 9-Valent HPV Vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeijing Wantai Biological Pharmacy Enterprise Co.,Ltd. Completes National Market Access for Its 9-Valent HPV Vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-29 16:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd. announced that its wholly-owned subsidiary, Xiamen Wantai Canghai Biotech Co., Ltd., has successfully completed the national market access process for its 9-valent human papillomavirus vaccine across mainland China. The vaccine has now gained access in all 31 provincial-level regions and is available through approximately 2,300 disease control and prevention centers, covering around 13,000 vaccination points nationwide. This milestone signifies that the domestically produced 9-valent HPV vaccine has secured the qualification for nationwide supply. Following this achievement, Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd.'s product portfolio now includes both its 9-valent and 2-valent HPV vaccines, creating a differentiated product matrix covering the female population aged 9 to 45. This effectively meets diverse vaccination needs across different age groups and consumer capabilities, further enriching the company's product line. The expansion enhances the company's comprehensive competitiveness in the HPV vaccine sector and lays a solid foundation for its long-term stable development. As the distribution of the 9-valent HPV vaccine continues to scale up, it is expected to gradually generate new revenue and profit growth, thereby improving the company's profitability.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1200","symbol_name":"软饮料","start_time":0,"source_url":"","article_id":"1123248946","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1123248946","pubTimestamp":1780043708,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd. announced that its wholly-owned subsidiary, Xiamen Wantai Canghai Biotech Co., Ltd., has successfully completed the national market access...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159646":"疫苗","603392":"万泰生物","BK1200":"软饮料","BK0239":"医药制造","BK1589":"北水核心资产","LU1981816686.USD":"EASTSPRING INV ASIAN MULTI FACTOR EQUITY \"A\" (USD) ACC","09633":"农夫山泉"},"translate_title":"北京万泰生物医药企业有限公司。9价HPV疫苗完成全国市场准入","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159646":1,"603392":1,"09633":1},"content_text":"Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd. announced that its wholly-owned subsidiary, Xiamen Wantai Canghai Biotech Co., Ltd., has successfully completed the national market access process for its 9-valent human papillomavirus vaccine across mainland China. The vaccine has now gained access in all 31 provincial-level regions and is available through approximately 2,300 disease control and prevention centers, covering around 13,000 vaccination points nationwide. This milestone signifies that the domestically produced 9-valent HPV vaccine has secured the qualification for nationwide supply. Following this achievement, Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd.'s product portfolio now includes both its 9-valent and 2-valent HPV vaccines, creating a differentiated product matrix covering the female population aged 9 to 45. This effectively meets diverse vaccination needs across different age groups and consumer capabilities, further enriching the company's product line. The expansion enhances the company's comprehensive competitiveness in the HPV vaccine sector and lays a solid foundation for its long-term stable development. As the distribution of the 9-valent HPV vaccine continues to scale up, it is expected to gradually generate new revenue and profit growth, thereby improving the company's profitability.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1123248946","isCrawlerRequest":true}